Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib efficacy in treatment-naive EGFR-mutant NSCLC by TP53 mutational status
2017-002626-20Phase 4Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Progression-free survival rate at 12 months. Started Jun 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2017-002626-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002626-20.